FGFR2 mutation

FGFR inhibition in #urothelialcarcinoma #bladdercancer at #ASCO23 - 1)The THOR Phase III trial in advanced #urothelialcarcinoma (UC) with FGFR2/3 mutations/fusions: Erdafitinib extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64,… https://t.co/AM7hNC5Db6 (@sonpavde)

What may also be relevant to GI cancers is the simultaneous Cancer Discovery publication at @ASCO #ASCO23 of RLY-4008- the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations with the clinical science symposium @CD_AACR with… https://t.co/YUjSUPRVYK (@VivekSubbiah)

🔥The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma @HEP_Journal https://t.co/TC5aUZdkWK 🔥Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma @trendscancer https://t.co/JCPSnToFCc (@ArndtVogel)

Fascinating case of cholangiocarcinoma with dual IDH1 and FGFR2 mutations - 2/3 trials mentioned @VivekSubbiah open at our site @kinghorncancer - sequencing and choice now can be tricky when patient may be eligible for multiple trials. @WIN_Consortium (@JiaJennyLiu)

Exceptional Response to Erdafitinib in #FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma: https://t.co/pFXGwH2DFc #PancSM #PancreaticCancer #MolecularInsights @jgong15 @DrArsenOsipov @DrHendifar (@JNCCN)

Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic #PancreaticCancer #OpenAccess in @JNCCN from @DrHendifar & colleagues @CedarsSinai https://t.co/pBdy0yqRC9 For young onset, KRAS wild type pancreatic cancers, don’t forget to look for alternative driver fusions. (@Aiims1742)

Erdafitinib for Advanced #urothelialcarcinoma and tumor FGFR2/3 mutations/fusions- updated results-101 treated-ORR 40%, median PFS 5.5 months (mo), DOR 6 mo (31% 1-year DOR), time to response 1.4 mo, OS 11.3 mo @y_loriot @AndreaNecchi-https://t.co/6ocRJgnLp0 @practiceupdate (@sonpavde)

Somatic FGFR2/3 mutations & advanced #urothelialcarcinoma-if both EV,Erdafitinib options, following may support erdafitinib before EV: 1) prospective trial data in specific population, 2) drug hitting specific target likely best used early (caveat-truism for all drugs,need data) (@sonpavde)

Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma @MJavle @MDAndersonNews #cancer https://t.co/qoGwdK9jmc (@OncLive)

Excellent oral presentations at #CCFAC2021 today. Our collaboration with @javlemilind on resistance mutations in FGFR2+ cholangiocarcinoma was presented. I also enjoyed the talk by @pashtoonkasi on the clinical utility of liquid biopsy in cholangiocarcinoma. #hpbcsm (@MasonIsraelPhD)

If you're not testing your cholangiocarcinoma patients for driver mutations, e.g. FGFR2, you are now undertreating your patients #ASCO20 (@marklewismd)

The trial required documentation of mutation in FGFR3 or fusion of FGFR2/3. Luminal 1 subtype which is less responsive to checkpoint inhibitors and has more frequent FGFR mutations might respond better to Erdafitinib. #bladdercancer #immunotherapy @BladderCancerMD (@anandoncologist)